0000950170-24-030479.txt : 20240312 0000950170-24-030479.hdr.sgml : 20240312 20240312215620 ACCESSION NUMBER: 0000950170-24-030479 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240308 FILED AS OF DATE: 20240312 DATE AS OF CHANGE: 20240312 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Brumm Joshua T CENTRAL INDEX KEY: 0001528826 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39509 FILM NUMBER: 24744469 MAIL ADDRESS: STREET 1: ZELTIQ AESTHETICS INC. STREET 2: 4698 WILLOW ROAD SUITE 100 CITY: PLEASANTON STATE: CA ZIP: 94588 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Dyne Therapeutics, Inc. CENTRAL INDEX KEY: 0001818794 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 364883909 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1560 TRAPELO ROAD CITY: WALTHAM STATE: MA ZIP: 02451 BUSINESS PHONE: (781) 786-8230 MAIL ADDRESS: STREET 1: 1560 TRAPELO ROAD CITY: WALTHAM STATE: MA ZIP: 02451 4 1 ownership.xml 4 X0508 4 2024-03-08 0001818794 Dyne Therapeutics, Inc. DYN 0001528826 Brumm Joshua T 1560 TRAPELO ROAD WALTHAM MA 02451 true true false false CEO & President true Common Stock 2024-03-08 4 M false 153931 5.54 A 708316 D Common Stock 2024-03-08 4 M false 209412 5.54 A 917728 D Common Stock 2024-03-08 4 S false 202238 25.30 D 715490 D Common Stock 2024-03-08 4 S false 160670 26.72 D 554820 D Common Stock 2024-03-08 4 S false 435 27.38 D 554385 D Common Stock 2024-03-11 4 M false 50000 5.54 A 604385 D Common Stock 2024-03-11 4 S false 40072 25.42 D 564313 D Common Stock 2024-03-11 4 S false 9928 26.10 D 554385 D Common Stock 2024-03-11 4 S false 7769 26.12 D 546616 D Common Stock 2024-03-11 4 S false 8618 25.93 D 537998 D Stock option (right to buy) 5.54 2024-03-08 4 M false 153931 0 D 2030-07-30 Common Stock 153931 0 D Stock option (right to buy) 5.54 2024-03-08 4 M false 209412 0 D 2030-07-30 Common Stock 209412 133269 D Stock option (right to buy) 5.54 2024-03-11 4 M false 50000 0 D 2030-07-30 Common Stock 50000 83269 D The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $25.20 to $26.19, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $26.20 to $27.18, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $27.27 to $27.49, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $25.00 to $25.75, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $26.01 to $26.10, inclusive. Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 10, 2021 and December 9, 2022. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $25.22 to $26.18, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $25.68 to $26.05, inclusive. Includes 513,913 unvested RSUs. The option was granted on July 31, 2020, with 100% of the option to vest upon the clearance date of an IND application submitted to the FDA by the Company with respect to one of its product candidates. On July 5, 2022, in connection with the clearance by the FDA of the Company's IND application for DYNE-251, the Compensation Committee determined that the performance condition had been achieved. The option was granted on July 31, 2020. The shares underlying the option vest over four years in sixteen equal installments beginning on October 31, 2020. /s/ Richard Scalzo, Attorney-in-Fact 2024-03-12